Medicis Pharmaceutical Corp. (MRX) Tops Q2 EPS by 33c; offers guidance

Medicis Pharmaceutical Corp. (NASDAQ: MRX) reported Q2 EPS of $0.90, $0.33 better than the analyst estimate of $0.57. Revenue for the quarter came in at $422.1 million versus the consensus estimate of $348.85 million.

"The outlook for Marex remains positive and we believe we are on track for a tenth year of sequential growth. We anticipate full year Adjusted Operating Profit to be approximately $280m to $290m, assuming more normalised market conditions in H2 2024, following the strong performance in the first half, momentum in our businesses and further progress executing our growth strategy."

For earnings history and earnings-related data on Medicis Pharmaceutical Corp. (MRX) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15